Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to ...
09 Julio 2019 - 6:05AM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing treatments that restore and
preserve vision for people with serious eye diseases, today
announced its entry into a worldwide licensing agreement with Aura
Biosciences for the use of Clearside’s Suprachoroidal Space (SCS)
Microinjector™ to deliver Aura’s proprietary drug candidates into
the SCS for the potential treatment of certain ocular cancers,
including choroidal melanoma.
Aura is developing a novel class of therapies,
viral nanoparticle conjugates, designed to selectively bind and
eliminate cancer cells without damaging surrounding normal tissues.
Aura is licensing Clearside’s proprietary SCS Microinjector as a
potential non-surgical alternative to intravitreal delivery of
Aura’s proprietary anti-cancer drug candidates, which may enable
the delivery of higher concentrations using a lower dose to the
choroid and adjacent areas. If the collaboration proves
successful following preclinical and proof-of-concept studies, Aura
may utilize the SCS Microinjector for certain future development
programs.
“Clearside is committed to expanding the global
reach of our SCS injection platform, and this collaboration with
Aura broadens the use of our technology into the ocular oncology
space,” said George Lasezkay, Pharm.D., J.D., Interim Chief
Executive Officer and Board Member of Clearside. “Drug delivery to
the SCS potentially offers several key advantages compared to
intravitreal, periocular or subretinal injections, including
repeatable, non-surgical drug administration to the SCS and target
tissues in the retina and choroid, avoidance of non-targeted
tissues, and strong bioavailability and durability. We believe Aura
is an ideal partner for our targeted SCS Microinjector that has the
potential to optimize dosing and administration of their ocular
anti-cancer drug candidates, with the goal of bringing promising
new treatments to patients suffering from ocular cancers such as
choroidal melanoma.”
Pursuant to the licensing agreement, Clearside
is eligible to receive payments related to pre-specified
development, regulatory and sales milestones, as well as royalties
on product sales that utilize the SCS Microinjector.
About Clearside
Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing treatments that
restore and preserve vision for people with serious eye diseases.
Clearside’s proprietary Suprachoroidal Space (SCS) Microinjector™
offers unprecedented access to the back of the eye where
sight-threatening disease often occurs. The Company’s SCS injection
platform is an inherently flexible, in-office, non-surgical
procedure, intended to work with established medications, new
formulations of medicines, as well as future therapeutic
innovations such as gene therapy. Clearside is headquartered in
Alpharetta, GA. For more information, please visit
www.clearsidebio.com.
Clearside Biomedical Cautionary
Note Regarding Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words such as “believe”, “expect”, “may”, “plan”,
“potential”, “will”, and similar expressions, and are based on
Clearside’s current beliefs and expectations. These forward-looking
statements include expectations regarding the potential benefits of
the SCS injection platform and the potential approval and
commercialization of XIPERE for the treatment of macular edema
associated with uveitis. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those reflected in such statements. Risks and uncertainties
that may cause actual results to differ materially include
uncertainties inherent in the conduct of clinical trials,
Clearside’s reliance on third parties over which it may not always
have full control, and other risks and uncertainties that are
described in Clearside’s Annual Report on Form 10-K for the year
ended December 31, 2018, filed with the U.S. Securities and
Exchange Commission (“SEC”) on March 15, 2019, and Clearside’s
other Periodic Reports filed with the SEC. Any forward-looking
statements speak only as of the date of this press release and are
based on information available to Clearside as of the date of this
release, and Clearside assumes no obligation to, and does not
intend to, update any forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor and Media
Contacts:
Jenny KobinRemy Bernardair@clearsidebio.com (678)
430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024